NASDAQ:EXASEXACT Sciences Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding EXACT Sciences Co. Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $85.88 +1.99 (+2.37 %) (As of 05/29/2020 04:00 PM ET) Add Compare Share Today's Range$82.06Now: $85.88▼$86.0050-Day Range$65.07MA: $77.95▼$86.2952-Week Range$35.25Now: $85.88▼$123.99Volume1.29 million shsAverage Volume1.39 million shsMarket Capitalization$12.86 billionP/E RatioN/ADividend YieldN/ABeta1.88 ProfileAnalyst RatingsAdvanced ChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Exact Sciences Corporation, a molecular diagnostics company, focuses on developing products for the early detection and prevention of various cancers in the United States. The company offers Cologuard, a non-invasive stool-based DNA screening test for the early detection of colorectal cancer and pre-cancer. It has license agreements with MAYO Foundation for Medical Education and Research; and Hologic, Inc. Exact Sciences Corporation was founded in 1995 and is headquartered in Madison, Wisconsin.Read More Beat the Market (BTM) Rank™ 3.5 Analyst's Opinion Consensus RatingEXACT Sciences has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 16 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $106.67, EXACT Sciences has a potential upside of 24.2% from its current price of $85.88.Amount of Analyst CoverageEXACT Sciences has been the subject of 10 research reports in the past 90 days, demonstrating strong analyst interest in this stock. Previous Next 3.1 Community Rank Outperform VotesEXACT Sciences has received 875 “outperform” votes. (Add your “outperform” vote.)Underperform VotesEXACT Sciences has received 549 “underperform” votes. (Add your “underperform” vote.)Community SentimentEXACT Sciences has received 61.45% “outperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about EXACT Sciences and other stocks. Vote “Outperform” if you believe EXAS will outperform the S&P 500 over the long term. Vote “Underperform” if you believe EXAS will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldEXACT Sciences does not currently pay a dividend.Dividend GrowthEXACT Sciences does not have a long track record of dividend growth. Previous Next 1.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, EXACT Sciences insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $677,332.00 in company stock.Percentage Held by InsidersOnly 2.20% of the stock of EXACT Sciences is held by insiders.Percentage Held by Institutions86.91% of the stock of EXACT Sciences is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for EXACT Sciences are expected to grow in the coming year, from ($1.64) to ($0.87) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of EXACT Sciences is -110.10, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of EXACT Sciences is -110.10, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioEXACT Sciences has a P/B Ratio of 5.07. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next Analyst Opinion: 3.5Community Rank: 3.1Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.6 5 -4 -3 -2 -1 -Overall Beat the Market Rank™1.65 out of 5 stars Industry, Sector and Symbol Stock Exchange NASDAQ Industry Commercial physical research Sub-IndustryBiotechnology SectorMedical Current SymbolNASDAQ:EXAS Previous Symbol CUSIP30063P10 CIK1124140 Webwww.exactsciences.com Phone608-284-5700Debt Debt-to-Equity Ratio0.64 Current Ratio6.09 Quick Ratio5.81Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$876.29 million Price / Sales14.68 Cash FlowN/A Price / Cash FlowN/A Book Value$16.95 per share Price / Book5.07Profitability EPS (Most Recent Fiscal Year)($1.49) Net Income$-83,990,000.00 Net Margins-10.04% Return on Equity-13.98% Return on Assets-7.70%Miscellaneous Employees4,110 Outstanding Shares149,750,000Market Cap$12.86 billion Next Earnings Date8/3/2020 (Estimated) OptionableOptionable NASDAQ:EXAS Rates by TradingView Receive EXAS News and Ratings via Email Sign-up to receive the latest news and ratings for EXAS and its competitors with MarketBeat's FREE daily newsletter. EXACT Sciences (NASDAQ:EXAS) Frequently Asked Questions How has EXACT Sciences' stock been impacted by COVID-19 (Coronavirus)? EXACT Sciences' stock was trading at $57.82 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, EXAS stock has increased by 48.5% and is now trading at $85.88. View which stocks have been most impacted by Coronavirus. Do Wall Street analysts recommend investors buy shares of EXACT Sciences? 16 Wall Street analysts have issued "buy," "hold," and "sell" ratings for EXACT Sciences in the last year. There are currently 16 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for EXACT Sciences. When is EXACT Sciences' next earnings date? EXACT Sciences is scheduled to release its next quarterly earnings announcement on Monday, August 3rd 2020. View our earnings forecast for EXACT Sciences. How were EXACT Sciences' earnings last quarter? EXACT Sciences Co. (NASDAQ:EXAS) released its earnings results on Wednesday, May, 6th. The medical research company reported ($0.71) EPS for the quarter, missing analysts' consensus estimates of ($0.59) by $0.12. The medical research company earned $347.80 million during the quarter, compared to the consensus estimate of $347.47 million. EXACT Sciences had a negative net margin of 10.04% and a negative return on equity of 13.98%. The company's revenue for the quarter was up 114.7% on a year-over-year basis. During the same period in the previous year, the firm posted ($0.66) EPS. View EXACT Sciences' earnings history. What guidance has EXACT Sciences issued on next quarter's earnings? EXACT Sciences issued an update on its first quarter 2020 After-Hours earnings guidance on Tuesday, April, 21st. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $348-348 million, compared to the consensus revenue estimate of $240.68 million. What price target have analysts set for EXAS? 16 Wall Street analysts have issued 12 month price targets for EXACT Sciences' stock. Their forecasts range from $70.00 to $135.00. On average, they expect EXACT Sciences' share price to reach $106.67 in the next year. This suggests a possible upside of 24.2% from the stock's current price. View analysts' price targets for EXACT Sciences. What are Wall Street analysts saying about EXACT Sciences stock? Here are some recent quotes from research analysts about EXACT Sciences stock: 1. According to Zacks Investment Research, "Exact Sciences exited the first quarter of 2020 with better-than-expected revenues, thanks to the Genomic Health acquisition. Higher Cologuard volumes boosted its legacy Screening business. Gross margin expansion and an overall strong solvency are encouraging as well. Continued strong demand for tests needed for cancer treatment mitigated the overall revenue impact. Delivery of critical care and accelerated launch of its telehealth site to lessen direct interactions with health care providers during the pandemic are noteworthy. However, fewer patient visits and surgery deferrals due to COVID-19 are concerning. Sole reliance on Cologuard and competitive headwinds are other major downsides. Rising expenses and operating loss also do not bode well. Overall, Exact Sciences has underperformed its industry over the past six months." (5/28/2020) 2. Canaccord Genuity analysts commented, "We are buyers of EXAS following the unusual 10% weakness in shares today, which we believe were part of the overall selloff today in diagnostics (and software stocks), where much of the alpha in the overall stock market has come from; and what we believe is likely certain funds pressuring EXAS following a cost effectiveness study published last week, but got a lot more attention today on the Street. We believe this is a buy-on- weakness opportunity on shares of EXAS given a handful of deep flaws used in the study." (9/10/2019) Has EXACT Sciences been receiving favorable news coverage? News headlines about EXAS stock have been trending somewhat negative on Sunday, InfoTrie Sentiment Analysis reports. InfoTrie identifies negative and positive news coverage by analyzing more than six thousand news and blog sources in real-time. The firm ranks coverage of companies on a scale of -5 to 5, with scores closest to five being the most favorable. EXACT Sciences earned a daily sentiment score of -1.0 on InfoTrie's scale. They also gave press coverage about the medical research company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an impact on the stock's share price in the near term. View the latest news aboutEXACT Sciences. Who are some of EXACT Sciences' key competitors? Some companies that are related to EXACT Sciences include Amgen (AMGN), Gilead Sciences (GILD), Celgene (CELG), Vertex Pharmaceuticals (VRTX), Regeneron Pharmaceuticals (REGN), Biogen (BIIB), Seattle Genetics (SGEN), Alexion Pharmaceuticals (ALXN), Incyte (INCY), BioMarin Pharmaceutical (BMRN), Alnylam Pharmaceuticals (ALNY), Neurocrine Biosciences (NBIX), Ionis Pharmaceuticals (IONS), Immunomedics (IMMU) and Exelixis (EXEL). View all competitors. What other stocks do shareholders of EXACT Sciences own? Based on aggregate information from My MarketBeat watchlists, some companies that other EXACT Sciences investors own include Novavax (NVAX), NVIDIA (NVDA), Alibaba Group (BABA), Micron Technology (MU), salesforce.com (CRM), Paypal (PYPL), Square (SQ), Advanced Micro Devices (AMD), Aduro BioTech (ADRO) and Netflix (NFLX). Who are EXACT Sciences' key executives? EXACT Sciences' management team includes the following people: Mr. Kevin T. Conroy, Chairman, Pres & CEO (Age 53)Mr. Jeffrey T. Elliott CFA, Chief Financial Officer (Age 41)Mr. Graham P. Lidgard, Chief Science Officer (Age 70)Mr. D. Scott Coward, Chief Admin. Officer, Sr. VP, Gen. Counsel & Sec. (Age 54)Mr. Mark Stenhouse, Pres of Cologuard (Age 52) What is EXACT Sciences' stock symbol? EXACT Sciences trades on the NASDAQ under the ticker symbol "EXAS." Who are EXACT Sciences' major shareholders? EXACT Sciences' stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Ensign Peak Advisors Inc (2.04%), Viking Global Investors LP (1.62%), Zevenbergen Capital Investments LLC (1.20%), Geode Capital Management LLC (1.07%), Jennison Associates LLC (0.96%) and Primecap Management Co. CA (0.93%). Company insiders that own EXACT Sciences stock include D Scott Coward, G Bradley Cole, Graham Peter Lidgard, Jacob A Orville, James Edward Doyle, Jeffrey Thomas Elliott, Katherine S Zanotti, Kevin T Conroy, Mark Stenhouse, Michael S Wyzga, Scott C Johnson and Thomas D Carey. View institutional ownership trends for EXACT Sciences. Which institutional investors are selling EXACT Sciences stock? EXAS stock was sold by a variety of institutional investors in the last quarter, including Jennison Associates LLC, Victory Capital Management Inc., Victory Capital Management Inc., Wasatch Advisors Inc., KBC Group NV, Nuveen Asset Management LLC, Kornitzer Capital Management Inc. KS, and Blair William & Co. IL. Company insiders that have sold EXACT Sciences company stock in the last year include G Bradley Cole, Jacob A Orville, James Edward Doyle, Jeffrey Thomas Elliott, Katherine S Zanotti, Kevin T Conroy, Mark Stenhouse, and Scott C Johnson. View insider buying and selling activity for EXACT Sciences. Which institutional investors are buying EXACT Sciences stock? EXAS stock was bought by a variety of institutional investors in the last quarter, including Ensign Peak Advisors Inc, ArrowMark Colorado Holdings LLC, Sachem Head Capital Management LP, Factory Mutual Insurance Co., Viking Global Investors LP, Eminence Capital LP, Spyglass Capital Management LLC, and Rothschild & Co. Asset Management US Inc.. View insider buying and selling activity for EXACT Sciences. How do I buy shares of EXACT Sciences? Shares of EXAS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is EXACT Sciences' stock price today? One share of EXAS stock can currently be purchased for approximately $85.88. How big of a company is EXACT Sciences? EXACT Sciences has a market capitalization of $12.86 billion and generates $876.29 million in revenue each year. The medical research company earns $-83,990,000.00 in net income (profit) each year or ($1.49) on an earnings per share basis. EXACT Sciences employs 4,110 workers across the globe. What is EXACT Sciences' official website? The official website for EXACT Sciences is www.exactsciences.com. How can I contact EXACT Sciences? EXACT Sciences' mailing address is 441 CHARMANY DRIVE, MADISON WI, 53719. The medical research company can be reached via phone at 608-284-5700. This page was last updated on 5/31/2020 by MarketBeat.com Staff
